D2G Oncology, Inc. proposes to develop a novel preclinical experimental platform that will effectively relate cancer drugs to genotypes (?D2G?) to predict pharmacogenomic interactions. D2G Oncology's innovative approach dramatically improves on established autochthonous mouse models of human cancer. These proven models allow controlled genomic alterations to initiate tumors in vivo in an appropriate immune-competent microenvironment and faithfully recapitulate progression of human cancer. D2G's innovative methods for the first time enable these animal models to become truly scalable and rigorously quantitative, and hence prac- tical to support drug discovery. D2G's approach can efficiently interrogate a large matrix of tumor genotypes to predict differential patient responses to therapies. Pharmaceutical companies are eager to obtain this infor- mation. D2G will significantly advance the state of the art in precision cancer therapy by helping pharma to rationally select candidate compounds to advance and better match them to patients. D2G's oncology platform will increase the success rate of clinical trials and lead to more effective personalized cancer treatments. The key innovation is a novel tumor barcoding and sequencing (Tuba-seq) pipeline. Every clonal tumor is uniquely barcoded, so the identity and number of cancer cells in each tumor can be readily quantified from bulk tumor-bearing tissues. Combined with lentiviral-mediated CRISPR/Cas9 somatic genome editing, tumor barcoding allows many predefined tumor genotypes to be generated all at once in individual animals and tracked separately. Tuba-seq enables many tens of experiments (which would each ordinarily require separate cohorts of mice) to be multiplexed into a single mouse. Compared with conventional genetically engineered mouse models, this approach enormously enhances scalability, introduces rigorous quantification, and reduces sources of variation. The overall goal of the proposed Direct Phase 2 SBIR project is to transform the Tuba-seq pipeline into a robust platform that can be marketed as a commercial service to pharmaceutical companies.
Specific aims are to (1) expand the panel of tumor suppressor genes that the platform interrogates and carefully calibrate their effect sizes and (2) rigorously validate the ability of the platform to resolve small but clinically meaningful differences in tumor suppressor gene-drug effect sizes with high statistical confidence, relying only on small cohorts of ani- mals. D2G will create the first practical and scalable preclinical experimental modeling approach that can assess how candidate drugs interact with diverse, precisely-engineered cancer genotypes to predict differential patient responses to therapy.
D2G Oncology, Inc. is developing a novel preclinical experimental platform that will efficiently relate cancer drugs to genotypes. The platform will provide critical information about how different genomic alterations cause cancer patients to respond differently to the same therapy. This information will enable pharmaceutical companies to develop cancer treatments that are more effective, and to identify the patients most likely to benefit from them, thus increasing the likelihood that new cancer therapies will succeed in clinical trials while advancing the promise of personalized medicine. !
